Summary of findings 2. Total cholesterol‐lowering efficacy of pitavastatin.
| Total cholesterol‐lowering efficacy ofpitavastatin | ||||||
|
Patient or population: participants with normal or abnormal lipid profiles Settings: ambulatory clinics Intervention: different fixed doses of pitavastatin Comparison: placebo or baseline | ||||||
| Pitavastatin dose |
Anticipated absolute effects mmol/L (95%CI) |
Percentage change from baseline (95% CI) | № of participants (trials) | Certainty of the evidence (GRADE) | Comments | |
| Total cholesterol before exposure to pitavastatina | Total cholesterol after exposure to pitavastatin | |||||
| 1 mg/day | 7.24 (6.67 to 7.82) |
5.55 (5.49 to 5.60) |
‐23.4 (‐24.2 to ‐22.7) |
777 (10) | ⊕⊕⊕⊕ high | Effect predicted from log dose‐response equation is ‐23.3% |
| 2 mg/day | 6.65 (6.33 to 6.97) |
4.84 (4.81 to 4.87) |
‐27.25 (‐27.65 to ‐26.84) |
2789 (32) | ⊕⊕⊕⊕ high | Effect predicted from log dose‐response equation is ‐27.3% |
| 4 mg/day | 7.21 (6.49 to 7.94) |
4.97 (4.87 to 5.07) |
‐31.1 (‐32.4 to ‐29.7) |
477 (7) | ⊕⊕⊕⊕ high | Effect predicted from log dose‐response equation is ‐31.2% |
| CI: Confidence interval | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
aMean baseline values.